Results 211 to 220 of about 72,161 (311)

Associations Between 40‐Year Trajectories of BMI and Proteomic and Epigenetic Aging Clocks: Deciphering Nonlinearity and Interactions

Aging Cell, Volume 25, Issue 2, February 2026.
In twins followed up over 40 years across adulthood, we examined associations between long‐term body mass index trajectories and downstream acceleration in proteomic and epigenetic aging. We further examined whether these associations showed statistical evidence for nonlinear patterns.
Gabin Drouard, M. Austin Argentieri, Aino Heikkinen, Miina Ollikainen, Jaakko Kaprio   +4 more
wiley   +1 more source

Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 803-816, February 2026.
Abstract Treatment with GLP‐1 receptor agonists (GLP‐1 RAs) is effective in reducing body weight in individuals with overweight and type 2 diabetes (T2D). However, measurements indicate that a considerable portion of the weight loss derives from fat‐free mass (FFM), including skeletal muscle, which may compromise metabolic health and physical function.
Viktor Aimelet, Jens Juul Holst
wiley   +1 more source

Guts, Glucose, and Gallbladders: The Protective Role of GLP-1/GIP Receptor Agonists Against Biliary Complications in Patients with Type 2 Diabetes and Inflammatory Bowel Disease. [PDF]

J Clin Med
Kazi MAI, Singh S, Haq N.
europepmc   +1 more source

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.

Cell Metabolism, 2017
J. Frias, E. Bastyr, L. Vignati, M. Tschöp, C. Schmitt, K. Owen, R. Christensen, R. DiMarchi   +7 more
semanticscholar   +1 more source

Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 826-839, February 2026.
Abstract Maternally inherited diabetes and deafness (MIDD) is a mitochondrial disorder usually caused by the variant m.3243A>G in the MT‐TL1 gene. We have proposed that diabetes in MIDD arises from a combination of insulin resistance and impaired β‐cell function that is more likely to occur in the presence of high skeletal muscle heteroplasmy and ...
Ahsen Chaudhry, David M. Thompson, Jean‐Pierre Chanoine   +2 more
wiley   +1 more source

GIP Regimen [PDF]

, 2020
openaire   +1 more source

Baseline characteristics in the SYNCHRONIZE™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for obesity in people with type 2 diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1490-1498, February 2026.
Abstract Aims Survodutide is an investigational glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double‐blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity—SYNCHRONIZE™‐1 in ...
Sean Wharton, Carel W. le Roux, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

Comparison of oral versus intravenous glucose exposure on plasma growth hormone levels: a crossover study in healthy volunteers. [PDF]

Pituitary
Vinten AK, Jørgensen NT, Budtz-Jørgensen E, Klose M, Andreassen M.   +4 more
europepmc   +1 more source

The value and impact of weight reduction from the perspective of people with type 2 diabetes in the United States

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1116-1125, February 2026.
Abstract Aims To understand the importance and potential impacts of reaching a lower weight or body mass index (BMI) from the perspectives of people with type 2 diabetes (T2D) across BMI levels. Materials and methods A cross‐sectional survey, informed by qualitative interviews, was administered to a sample representative of the US T2D population by BMI.
Melissa M. Ross, Sarah Mulnick, Kristina S. Boye, Ashley Samuelson, Vivian Thuyanh Thieu, Christine Longuet, Jennifer Glass, Meredith M. Hoog   +7 more
wiley   +1 more source

Xenin-Derived Peptides: Multifaceted Regulators and Therapeutic Innovations in Metabolic Diseases. [PDF]

Drug Des Devel Ther
Gong B, Liu X, Hu G, Li T, Chen F, Sun X, Sun L, Xu Y.   +7 more
europepmc   +1 more source